Medtech Helitree completed the minority investment in Pathology Asia.

Synopsis

Medtech Helitree, a private equity firm, completed the minority investment in Pathology Asia, a medical technology and diagnosis service provider company. Financial terms were not disclosed.

Principals

target

Pathology Asia Holdings

bidder

Medtech Helitree

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

latham & watkins

HQ - New York, United States

legal advisors

target

5552

Deals

£ 3,609.30 B

Total Value